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Background: The purpose of the research was to find out the factors which influence plasma N-terminal pro-brain
natriuretic peptide (NT-proBNP) levels, then to assess whether preoperative plasma NT-proBNP levels could predict
postoperative outcomes of cardiac surgery.
Methods: Between November 2008 and February 2010,225 patients who underwent cardiac surgery in our
department were included in the study. The mean age was 61.25 ± 12.54 years, and 156 (69.3%) patients were male.
NT-proBNP, CK-MB, cTnT and creatinine levels were measured preoperatively and 24 hours after operation.
Postoperatively outcomes including ventilation time, length of stay in ICU and hospital, and mortality were closely
monitored. The endpoints includes: 1) use of inotropic agents or intra-aortic balloon pump ≥24 h; 2) creatinine
level elevated to hemodialysis; 3) cardiac events; 4) ICU stay ≥5d; 5) ventilation dependence≥ 72 h; 6) deaths
within 30 days of surgery.
Results: NT-proBNP concentrations (median [interquartile range]) increased from 728.4 pg/ml (IQR 213.5 to
2551 pg/ml) preoperatively to 1940.5 pg/ml (IQR 995.9 to 3892 pg/ml) postoperatively (P = 0.015). Preoperative atrial
fibrillation, NYHA class III/IV, ejection fraction, pulmonary arterial pressure, left ventricle end-diastolic diameter
(LVEDD), preoperative plasma creatinine and cTnT levels were significantly associated with preoperative NT-proBNP
levels in univariate analysis. The preoperative NT-proBNP was closely related to ventilation time (P = 0.009), length of
stay in ICU (P = 0.004) and length of stay in hospital (P = 0.019). Receiver operating characteristic curves
demonstrated a cut-off value above 2773.5 pg/ml was the best cutoff (sensitivity of 63.6% and specificity of 80.8%)
to predict the mortality within 30d of surgery.
Conclusions: Preoperative plasma NT-proBNP level presents a high individual variability in patients undergoing
cardiac surgery. NYHA classification, ejection fraction, pulmonary arterial pressure, LVEDD, atrial fibrillation,
preoperative plasma creatinine, and cTnT levels are significantly associated with preoperative NT-proBNP levels.
Preoperative NT-proBNP is a valuable marker in predicting postoperative outcomes.
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Figure 1 Distribution of preoperative NT-proBNP.
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Brain natriuretic peptide (BNP) is a cardiac hormone
released by ventricular myocytes in response to ventricu-
lar dysfunction and wall stress. Since it was originally
described, BNP has been used mainly in the field of car-
diology. The predictive value of NT-proBNP in cardiac
surgery has only been assessed in a small number of
studies. The main objective of this study was to assess
the factors which influence the level of NT-proBNP and
the predictive value of NT-proBNP.
Methods
Between November 2008 and February 2010, 225 pa-
tients who underwent cardiac surgery in our depart-
ment were included in the study. The mean age was
61.25 ± 12.54 years, and 156 (69.3%) patients were
male. 85 patients had valve repair or replacement, in-
cluding mitral valve repair or replacement, aortic valve
replacement, tricuspid valve replacement. 105 patients
had coronary artery bypass grafting (CABG), including
71 off-pump CABG and 34 conventional CABG. 16
patients had valve replacement or repair concomitant
CABG. 7 patients had congenital heart disease repair
operation, including atrial septal defect repair, ventricu-
lar septal defect repair and Fallot’s syndrome repair. 12
patients had replacement of thoracic aorta. 14 patients
had concomitant atrial fibrillation inflation. 154 patients
had operations under cardiopulmonary bypass (CPB).
The mean CPB and cross-clamp times were 103.31 ±
43.56 min and 54.47 ± 24.37 min, respectively.
Past medical and surgical histories were determined by
review of previous records. Preoperative plasma creatinine,
CK-MB, cTnT and echocardiogram data were reported.
The plasma concentrations of NT-proBNP were obtained
before operation and 24 hours after the end of the surgery.
Standardized anesthesia was used in all patients, and
each operation was performed through a median ster-
notomy. Postoperatively all patients had routine care
with close monitoring of the cardiovascular system, renal
output and other vital signs. Ventilation time, ICU stay
time and hospital time were followed.
The clinical endpoints included: 1) use of high doses of
inotropic agents or intra-aortic balloon pump ≥24 h; 2)
creatinine level elevated to hemodialysis; 3) cardiac events;
4) ICU stay ≥5d; 5) ventilation dependence ≥ 72 h; 6)
deaths within 30 days of surgery.
Statistical methods
Continuous variables are expressed as mean ± standard
deviation (SD) or as median and interquartile range
(IQR). Categorical variables are shown as numbers(n)
and percentages (%). Mann–Whitney U-test was used to
compare the results between groups of numerical data
and Spearman rank was used for correlations betweencontinuous variables. The utility of BNP as a prognostic
indicator of postoperative outcomes was evaluated using
receiver operating characteristic (ROC) curves. A p value
of <0.05 was considered statistically significant. Data
were analyzed using a statistical software program (SPSS
for Windows 11.5).
Results
The preoperative NT-proBNP ranged from 19.3 pg/mL to
35000 pg/mL (median 728.4, IQR 213.5 to 2551 pg/mL).
The postoperative NT-proBNP ranged from 132.1 pg/mL
to 35000 pg/mL (median 1940.5, IQR 995.9 to 3892 pg/
mL). Distribution of preoperative and postoperative NT-
proBNP level showed in Figure 1 and 2. The difference be-
tween the preoperative and postoperative NT-proBNP
level was statistically significant (p = 0.015) in paired t-test.
Also there was a significant correlation between the pre-
operative NT-proBNP concentration and the postopera-
tive concentration (r = 0.526, p < 0.001).
The correlation between preoperative patient character-
istics and NT-proBNP level were shown in Table 1.Uni-
variate analysis showed that preoperative atrial fibrillation
(Af), New York heart association (NYHA) class III/IV,
ejection fraction (EF), pulmonary arterial pressure, left
ventricle end-diastolic diameter (LVEDD), preoperative
creatinine and cTnT were significantly associated with
preoperative NT-proBNP levels. Furthermore, patients
undergoing valvular surgery had higher NT-proBNP levels
compared to patients undergoing CABG.
A total of 11 deaths (4.89%) occurred after surgery.
Major death cause included postoperative heart failure,
neurologic deficit, postoperative renal failure, acute lung
failure and sepsis. Median NT-proBNP level in patients
Figure 2 Distribution of postoperative NT-proBNP.
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and 630.5 pg/mL (p = 0.016), respectively.
ROC curves demonstrated the assessment of the
prognostic performance of an elevated NT-ProBNP to
predict the mortality within 30d of surgery (Figure 3).
The area under the curve (AUC) was 0.738 (p = 0.008,
95% Confidence Interval 0.58-0.89). A NT-proBNP of
2773.5 pg/ml was the best cutoff (sensitivity of 63.6%
and specificity of 80.8%).
In the analysis, the preoperative NT-proBNP showed a
significant influence on the need for ICU length of stay
(LOS), hospital LOS and ventilation time (Table 2).
Discussion
BNP is originally isolated from the porcine brain, al-
though the highest concentration of BNP is actually
found in the heart rather than in the brain. It is a cardiac
hormone released by ventricular myocytes in responseTable 1 The correlation between preoperative patient charac
Values Median N
Age (y) 61.25 ± 12.54 -
Female/male 156/69 1048/705.6
NYHA I-II/NYHA III-IV 97/128 277.0/1176
LVEF 0.60 ± 0.11 -
LVEDD (mm) 56.29 ± 35.93 -
Pulmonary pressure (mmHg) 46.43 ± 17.49 -
Preoperative Cr (μmol/L) 86.66 ± 27.01 -
Preoperative CK-MB (IU/L) 20.31 ± 33.23 -
Preoperative cTnT (μg/L) 0.13 ± 0.57 -
Preoperative Af/no 56/169 2148.5/467
CABG/valvular surgery 115/88 436.7/1374to ventricular dysfunction and wall stress [1]. Probrain
natriuretic peptide is a 108 amino-acid propeptide synthe-
sized by myocytes, predominantly from the left ventricle,
in response to the increased wall stretch. When released,
it is cleaved into 2 fragments: the active brain peptide
(BNP) which has the function of natriuresis, diuresis and
vasorelaxation [2], and the N-terminal amino acid se-
quence (NT-proBNP). In rapid time, both BNP and
NT-proBNP have emerged as established cardiovascular
biomarkers, especially in heart failure, hypertension, acute
coronary syndrome or stable ischemic cardiac disease [3].
The main objective of our study was to find out the fac-
tors which influence preoperative plasma NT-proBNP
levels, then to assess the predictive value of BNP in car-
diac surgery.
Steady-state levels of NT-proBNP are as much as four-to
six-fold higher than BNP. We used NT-proBNP instead of
BNP because of its longer plasma half-life (60-120 min).
The longer half-life of NT-proBNP suggests it is more
independent of inter- and intra-individual variations [4].
Furthermore, molecules of BNP are unstable at room tem-
perature and start degrading immediately after blood draw
if not processed. And in their relation to clinical charac-
teristics and prognostic performance in a large popula-
tion of patients with heart failure, BNP and NT-proBNP
showed subtle differences [5]. This is why we decided to
use NT-proBNP in our study.
There is a wide individual variation in plasma NT-
proBNP values. As a general guideline, in young, healthy
adults, 90% will have BNP <25 pg/ml and NTproBNP
≤70 pg/ml [6]. Our study showed that the preoperative
NT-proBNP ranged from 19.3 pg/mL to 35000 pg/mL
(median 728.4, IQR 213.5 to 2551 pg/mL). Univariate
analysis showed that preoperative atrial fibrillation,
NYHA class III/IV, LVEF, pulmonary pressure, LVEDD,
preoperative creatinine, preoperative cTnT were signifi-
cantly associated with preoperative NT-proBNP levels.
NT-proBNP had a significant positive correlation withteristics and NT-proBNP level












Figure 3 The assessment of the prognostic performance of an
elevated NT-ProBNP to predict the mortality within 30d of
surgery.
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correlation with LVEF and NYHA classification, respect-
ively. This indicates that NT-proBNP is released increas-
ingly from the left ventricle when wall tension or stretch
increased as a consequence of volume overload or as left
ventricular function deteriorates [7]. Also high NT-proBNP
levels are associated with increased creatinine levels and
kidney failure. Besides of a reduced renal clearance of
NTproBNP, increased cardiac afterload caused by fluid re-
tention is a possible explanation [8]. Experimental and clin-
ical studies have suggested that atrial volume, pressure and
wall stretch are the main determinants of the activation of
these peptides and are all potentially altered in atrial fibrilla-
tion [9], so atrial fibrillation is also a risk factor of increased
NT-proBNP. Furthermore, our research found that patients
undergoing valvular surgery had higher NT-proBNP levels
compared to patients undergoing CABG. We think that
patients with valvular diseases had higher heart overload
and wall tension than patients with coronary artery
diseases.
The postoperative NT-proBNP ranged from 132.1 pg/mL
to 35000 pg/mL (median 1940.5, IQR 995.9 to 3892 pg/mL).Table 2 Preoperative NT-proBNP as predictor of surgical
outcome
Values r P value
ICU LOS (d) 3.45 ± 8.17 0.194 0.004
Hospital LOS (d) 19.20 ± 14.44 0.157 0.019
Time of ventilation (h) 21.88 ± 35.19 0.177 0.009The difference between the preoperative and postopera-
tive NT-proBNP level was statistically significant (p =
0.015). Previous studies demonstrated that BNP decreases
when the aortic clamp is applied and the heart is isolated
from circulation. Then there is a minor increase in BNP
concentrations following cardiac reperfusion [10]. 24 h
post-CPB it arrived its peak value, and returned to the pre-
operative baseline values 3 weeks after surgery [11]. The
postoperative peak concentration of plasma NT-proBNP
correlated with the preoperative plasma NT-proBNP con-
centration (r = 0.526, p < 0.001) in our research. This find-
ing offers a possible explanation why the outcomes after
cardiac surgery can be predicted by the preoperative
plasma concentration.
A variety of multifactorial risk indexes have been des-
cribed to help preoperative risk assessment of patients
undergoing cardiac surgery. Some studies had focused on
the predictive value of preoperative NT-proBNP [12,13].
Hutfless et al. considered that BNP levels > 385 pg/ml
could predict the postoperative complications and one-
year mortality after heart surgery [14]. Sodeck’s research
showed increased levels of NT-proBNP (>647 pg/ml) indi-
cated unfavorable outcome [15]. Grescenzi et al. showed
that postoperative NT-proBNP levels are associated with
in-hospital mortality and prolonged ICU stay after CABG
surgery [16]. Our study demonstrated that a NT-proBNP
of 2773.5 pg/ml was the best cutoff (sensitivity of 63.6%
and specificity of 80.8%) to predict the mortality within
30d of surgery. In our analysis, median NT-proBNP level
in patients with unfavorable clinical end points had sig-
nificantly higher NT-proBNP level than those without
(1998.5 pg/ml Vs. 630.5 pg/ml, p = 0.016). At the same
time, the preoperative NT-proBNP showed a significant in-
fluence on the ICU LOS, hospital LOS and ventilation time.
So NT-proBNP may be become a clinical routine bio-
marker capable of predicting patients’ perioperative and
early postoperative risk because of it is convenient, quick
and not expensive. The quantitative cut-off values may be
used by physicians in their decision to delay heart surgery
in order to further ameliorate the patient. This might be
through diuresis, and NT-proBNP level could be quantita-
tively followed until it reaches more reassuring levels.
Conclusion
In conclusion, preoperative plasma NT-proBNP level pre-
sents a high individual variability in patients undergoing
cardiac surgery. The risk factors of preoperative elevated
NT-proBNP levels include NYHA classification, EF, pul-
monary arterial pressure, LVEDD, Af, preoperative plasma
creatinine, and cTnT level. Preoperative NT-proBNP is a
valuable marker in predicting postoperative mortality and
bad outcome in patients undergoing heart surgery.
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